hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-03-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
=== Chemical modifications === Chitosan contains the following three functional groups: C2-NH2, C3-OH, and C6-OH. C3-OH has a large spatial site resistance and therefore is relatively difficult to modify. C2-NH2 is highly reactive for fine modifications and is the most common modifying group in chitosan. In chitosan, although amino groups are more prone to nucleophilic reactions than hydroxyl groups, both can react non-selectively with electrophilic reagents such as acids, chlorides, and haloalkanes to functionalize them. Since chitosan contains a variety of functional groups, it can be functionalized in different ways such as phosphorylation, thiolation, and quaternization to adapt it to specific purposes.
Examining rodents and their offspring, Brenner has showed that rodent postpartum mothers are under severe metabolic stress to their NAD system. Supplementing rodent mothers with NR increases maternal weight loss, advances juvenile development and provides long lasting neurodevelopmental advantages into adulthood. Considering citrin deficiency as a lean MASLD syndrome, he identified accumulation of glycerol-3-phosphate and activation of ChREBP as the mechanism of both elevated expression of FGF21 and elevated lipogenic transcription in this rare disease. Brenner is an author of more than 200 peer-reviewed publications. He was the senior editor of the 2004 book, Oncogenomics: Molecular Approaches to Cancer. Brenner is both cautious and critical of research that promotes claims of anti-aging and longevity. After writing a favorable review of Steven Austad's book Methuselah's Zoo, he reviewed Lifespan: Why We Age – and Why We Don't Have To by David A. Sinclair, summarizing it as "an influential source of misinformation on longevity, featuring counterfactual claims about longevity genes being conserved between yeast and humans, the existence of supposed activators of these genes, and claimed successful age reversal in mice based on partial reprogramming." Brenner published a major review of sirtuins in 2022 entitled "Sirtuins are not conserved longevity genes".
During 1990, in the capital city of Mogadishu, the residents were prohibited from gathering publicly in groups greater than three or four. Fuel shortages, inflation, and currency devaluation impacted the economy. A thriving black market existed in the centre of the city as banks experienced shortages of local currency for exchange. Harsh exchange control regulations were introduced to prevent export of foreign currency. Although no travel restrictions were placed on foreigners, photographing many locations was banned. During daytime in Mogadishu, the appearance of any government military force was extremely rare. Alleged late-night operations by government authorities, however, included "disappearances" of individuals from their homes. In 1991, the Barre administration was ousted by a coalition of clan-based opposition groups, backed by Ethiopia's then-ruling Derg regime and Libya. Following a meeting of the Somali National Movement and northern clans' elders, the northern former British portion of the country declared its independence as the Republic of Somaliland in May 1991. Although de facto independent and relatively stable compared to the tumultuous south, it was not recognised by any foreign government, until Israel recognised it in 2025.
Sources: en.wikipedia.org
Inquiries sent to the IDF regarding the experiences of these health care workers received a statement from a spokesperson that did not directly confirm whether investigations into the shootings of preteen children had been conducted or if any soldiers faced disciplinary action for firing at them. In response to claims alleging that the report was based on "fabricated evidence", The New York Times issued a statement defending the integrity of the piece, emphasizing that it had undergone rigorous editing and verification, including consultations with experts and the use of supporting photographs, which they deemed "too horrific for publication." De Volkskrant interviewed 17 doctors who had volunteered during the Gaza war. Fifteen of them reported seeing children with "a single gunshot wound to the head and/or chest." These doctors reported seeing 114 children injured this way. In response, former Commander of the Royal Netherlands Army Mart de Kruif told the paper, "If you're seeing a high number of gunshot wounds to the chest area and the head, that’s not collateral damage – that’s deliberate targeting." In one documented case, a girl was reportedly shot and killed while in her mother's arms. In June 2026, a 94-page report by the UN Independent International Commission of Inquiry on the Occupied Palestinian Territory concluded there were reasonable grounds to determine that Israeli forces directly targeted children in Gaza using snipers and quadcopter drones.
He concluded that perineurial cysts should be considered in patients with gradually worsening sacral nerve symptoms when imaging or surgery fails to reveal a herniated disc. In 1953, Dr. Isadore Tarlov published a monograph titled Sacral Nerve-Root Cysts: Another Cause of the Sciatic or Cauda Equina Syndrome, which compiled his anatomical, histological, and clinical research on perineurial cysts. The book combined scientific analysis with case studies to illustrate the symptoms, surgical techniques, and outcomes associated with sacral cysts. In Chapter 8, titled "Clinical Significance", Tarlov presented ten patient case reports documented between 1948 and 1952, four of which involved surgeries he personally performed. The remaining cases were managed by other surgeons using various techniques. Reported symptoms included pain, paresthesia, numbness (e.g., of the penis, thigh, buttocks, rectum, or vagina), urinary incontinence, and foot weakness with absent ankle reflex. Complete surgical removal of isolated cysts often led to full recovery, while patients with multiple cysts saw more limited improvement due to conservative surgical approaches. He concluded the monograph by urging increased clinical awareness of these lesions, stating that perineurial cysts may be a surgically treatable cause of sciatic and sacrococcygeal syndromes.
The Kingdom of Kucha, the most populous oasis in the Tarim Basin, occupied a strategic position on the Northern Silk Road, which brought it prosperity, and made it a wealthy center of trade and culture. Kucha was part of the Silk Road economy, and was in contact with the rest of Central Asia, including Sogdiana and Bactria, and thus also with the cultures of India, Iran, and coastal areas of China. Early visitors are known, such as Maes Titianus. Since the 2nd century CE, under the auspices of the Han dynasty and the Kushan Empire, numerous great Buddhist missionaries passed through the Tarim Basin on their way to China, such as the Parthian An Shigao, the Yuezhis Lokaksema and Zhi Qian, or the Indian Chu Sho-fu (竺朔佛). Culture flourished, and Indian Sanskrit scriptures were being translated by the Kuchean monk and translator Kumarajiva (344–413 CE), himself the son of a Buddhist man from Kashmir and a Kuchean princess, sister of the King. The 1st Style, sometimes called "First Indo-Iranian style" to denote influences from India and Central Asia, covers a period from 300 to 500 CE, and is characterized by Gandharan themes and orange and green hues, having a strong flavour of India: female dancers and musicians are often naked or half-naked with full breasts. The art of these paintings is quite refined, and forms the "Classical" period of the art of Kizil: the shades are delicate, the lines are fine and elegant, the colors blend progressively to give a sense of texture and volume.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.